ContractDiscovery Collaboration and License Agreement • August 7th, 2019 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
AMENDMENT NO. 1 TO AMENDED AND RESTATED DISCOVERY COLLABORATION AND LICENSE AGREEMENTDiscovery Collaboration and License Agreement • November 10th, 2021 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 to the Amended and Restated Discovery Collaboration and License Agreement (“First Amendment”) is made and entered into, effective as of [______], 2021 (“First Amendment Effective Date”), by and between Harpoon Therapeutics, Inc., a Delaware corporation (“Harpoon”), and AbbVie Biotechnology Ltd., a Bermuda corporation (“AbbVie”). Harpoon and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
DISCOVERY COLLABORATION AND LICENSE AGREEMENT between BICYCLETX LIMITED and GENENTECH, INC. Dated as of February 21, 2020Discovery Collaboration and License Agreement • March 10th, 2020 • BICYCLE THERAPEUTICS PLC • Pharmaceutical preparations • New York
This Discovery Collaboration and License Agreement (the “Agreement”) is made and entered into effective as of February 21, 2020 (the “Effective Date”) by and between BicycleTx Limited, a company incorporated in England and Wales (“BicycleTx”), and Genentech, Inc., a Delaware corporation (“Genentech”). BicycleTx and Genentech are referred to herein individually as a “Party” and collectively as the “Parties”.
DISCOVERY COLLABORATION AND LICENSE AGREEMENT between HARPOON THERAPEUTICS, INC. and ABBVIE BIOTECHNOLOGY LTD. Dated as of October 10, 2017Discovery Collaboration and License Agreement • October 24th, 2018 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Discovery Collaboration and License Agreement (the “Agreement”) is made and entered into effective as of October 10, 2017 (the “Effective Date”) by and between Harpoon Therapeutics, Inc., a Delaware corporation (“Licensor”), and AbbVie Biotechnology Ltd., a Bermuda corporation (“AbbVie”). Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
DISCOVERY COLLABORATION AND LICENSE AGREEMENTDiscovery Collaboration and License Agreement • May 9th, 2019 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances)
This First Amendment (the “First Amendment”) to the Discovery Collaboration and License Agreement dated October 10, 2017 (the “Agreement”) by and between Harpoon Therapeutics, Inc., a Delaware corporation (“Licensor”), and AbbVie Biotechnology Ltd., a Bermuda corporation (“AbbVie”) is made effective as of the date of the final signature to this First Amendment. Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ContractDiscovery Collaboration and License Agreement • February 28th, 2023 • BICYCLE THERAPEUTICS PLC • Pharmaceutical preparations
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
AMENDED AND RESTATED DISCOVERY COLLABORATION AND LICENSE AGREEMENT betweenDiscovery Collaboration and License Agreement • March 12th, 2020 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amended and Restated Discovery Collaboration and License Agreement (the “Agreement”) is made and entered into effective as of 20 November, 2019 (the “Amended Effective Date”) by and between Harpoon Therapeutics, Inc., a Delaware corporation (“Harpoon”), and AbbVie Biotechnology Ltd., a Bermuda corporation (“AbbVie”). Harpoon and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
